Research library

B

grade

A 29-year-old man with Prader-Willi syndrome lost 108.7 kg over 18 months using sequential incretin-based therapy, but this is a single case report and results may not be generalizable.

Total weight loss of 58.8% (-108.7 kg) at 18 months.

summary

C

grade

The combination of retatrutide and cagrilintide shows promise for enhancing weight loss and metabolic outcomes in a rodent model, but further research is needed to determine its relevance to human obesity treatment.

Not reported in abstract.

summary

D

grade

GLP-1 receptor agonists may influence the oral microbiome in patients with obstructive sleep apnea, but the clinical implications are not yet clear.

Not reported in abstract.

summary

C

grade

The combination of retatrutide and cagrilintide shows promise in enhancing weight loss and metabolic outcomes in obese male rats, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary

B

grade

Plasma is a more suitable matrix for detecting retatrutide than urine, with a detection window of approximately 56 days after administration.

Limits of detection (LOD) were 6.14 ng/mL in plasma and 2.44 ng/mL in urine.

summary

B

grade

Plasma is a more suitable matrix for detecting retatrutide than urine, with a detection window of approximately 56 days post-administration.

Limits of detection in plasma were 6.14 ng/mL and in urine were 2.44 ng/mL.

summary

D

grade

Glycemic control accounts for less than 20% of cardiovascular event reduction with incretin therapies, indicating other mechanisms are significant.

Glycemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events.

summary

D

grade

This study presents a validated LC-HRMS method that can accurately quantify GLP-1 receptor agonists, including retatrutide, with high sensitivity and specificity.

Mean recoveries of 113.7-118.4% for marketed formulations.

summary

B

grade

Clinicians should be aware of the potential risks associated with unregulated peptides like retatrutide, especially in patients with type 1 diabetes, where management can be complicated by concurrent illnesses.

Peak ketonaemia reached 4.3 mmol/L.

summary

D

grade

Not reported in abstract.

summary

B

grade

Retatrutide increased the force of contraction in isolated human atrial preparations, but its clinical relevance and implications for patient care remain unclear.

Cumulatively applied retatrutide starting at 10 nM elevated FOC in HAP in a concentration- and time-dependent manner.

summary

B

grade

Retatrutide use outside of clinical trials is associated with less than half the weight loss seen in trials and significant cardiovascular symptom burden.

7.2% body weight loss at 6-12 months for compounded retatrutide users, n=531, P=0.004.

summary

A

grade

Retatrutide treatment was associated with significant reductions in several cardiovascular risk biomarkers in adults with obesity, but the clinical implications of these findings require further investigation.

High-sensitivity C-reactive protein was reduced by -54.8% in Study 2.

summary

D

grade

Current evidence suggests a potential link between GLP-1 receptor agonists and neuropsychiatric disorders, but causality has not been established.

Not reported in abstract.

summary

C

grade

Retatrutide may partially improve cognitive function in diabetic rats, but its effects are limited and not fully understood. Further research is necessary to determine its relevance to human conditions.

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

C

grade

Retatrutide may partially improve cognitive deficits in diabetic rats, but its relevance to human diabetes remains unclear.

Retatrutide-treated diabetic rats showed preserved overall Morris Water Maze performance relative to untreated diabetic rats.

summary

A

grade

Obesity drugs vary in weight loss efficacy and adverse events; emerging agents like retatrutide show potential but with low certainty. Clinicians should weigh benefits against harms in shared decision-making.

Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce 13.1-14.6% weight loss; very low to low certainty.

summary

D

grade

Not reported in abstract.

summary

D

grade

Emerging obesity therapies like retatrutide show promise in reducing weight and improving related complications, but long-term safety and access are key considerations.

Retatrutide produced weight reductions exceeding 25%.

summary

D

grade

Obesity medications, especially GLP-1 receptor agonists, may offer benefits beyond weight loss, but specific outcomes are not detailed.

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary